Arcus to collaborate with astrazeneca on registrational trial for domvanalimab, arcus's novel anti-tigit antibody, plus imfinzi® in stage iii nsclc

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced a collaboration with astrazeneca (lse/sto/nasdaq: azn) to evaluate domvanalimab (ab154), arcus's investigational anti-tigit antibody, in combination with imfinzi (durvalumab) in a registrational phase 3 clinical trial in patients with unresectable stage iii non-small cell lung cancer (nsclc). imfinzi is the only im
RCUS Ratings Summary
RCUS Quant Ranking